Claritas Pharmaceuticals Inc. buy melinda
Start price
22.06.17
/
50%
€2.16
Target price
16.11.17
€4.04
Performance (%)
-16.54%
End price
16.11.17
€1.80
Summary
This prediction ended on 16.11.17 with a price of €1.80. The price of Claritas Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.54%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Claritas Pharmaceuticals Inc. | - | - | - | - |
| iShares Core DAX® | -0.079% | -3.039% | 13.992% | 14.646% |
| iShares Nasdaq 100 | 0.247% | 6.421% | 36.232% | 55.769% |
| iShares Nikkei 225® | 1.918% | 0.675% | 10.784% | 5.212% |
| iShares S&P 500 | 0.146% | 4.708% | 29.832% | 48.430% |
Comments by melinda for this prediction
In the thread Claritas Pharmaceuticals Inc. diskutieren
zu folgen
22. Juni (Reuters) - Kalytera Therapeutics Inc. :: Kalytera Therapeutics Inc. - Robert Farrell, JD, Präsident und CFO von Kalytera, wird die Rolle des Interim Chief Executive Officer übernehmen. Kalytera Therapeutics - erwartet für Patienten in einer klinischen Phase-2-Studie zur Beurteilung cbd beginnen Einschreibung ...
(Vom Mitglied beendet)
Stopped prediction by melinda for Claritas Pharmaceuticals Inc.
Claritas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.16
22.06.17
22.06.17
€4.04
16.11.17
16.11.17
-16.54%
16.11.17
16.11.17
